205 related articles for article (PubMed ID: 11243951)
1. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.
Wencker M; Fuhrmann B; Banik N; Konietzko N;
Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951
[TBL] [Abstract][Full Text] [Related]
2. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
Sclar DA; Evans MA; Robison LM; Skaer TL
Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
Dirksen A; Dijkman JH; Madsen F; Stoel B; Hutchison DC; Ulrik CS; Skovgaard LT; Kok-Jensen A; Rudolphus A; Seersholm N; Vrooman HA; Reiber JH; Hansen NC; Heckscher T; Viskum K; Stolk J
Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1468-72. PubMed ID: 10556107
[TBL] [Abstract][Full Text] [Related]
4. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
5. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
Abboud RT; Ford GT; Chapman KR
Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045
[TBL] [Abstract][Full Text] [Related]
6. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
[TBL] [Abstract][Full Text] [Related]
7. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.
Tonelli AR; Rouhani F; Li N; Schreck P; Brantly ML
Int J Chron Obstruct Pulmon Dis; 2009; 4():443-52. PubMed ID: 20054436
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749
[TBL] [Abstract][Full Text] [Related]
9. [Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Pneumologie; 1998 Oct; 52(10):545-52. PubMed ID: 9847632
[TBL] [Abstract][Full Text] [Related]
10. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.
Dawkins PA; Dawkins CL; Wood AM; Nightingale PG; Stockley JA; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1338-44. PubMed ID: 19164359
[TBL] [Abstract][Full Text] [Related]
11. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry.
Eden E; Hammel J; Rouhani FN; Brantly ML; Barker AF; Buist AS; Fallat RJ; Stoller JK; Crystal RG; Turino GM
Chest; 2003 Mar; 123(3):765-71. PubMed ID: 12628876
[TBL] [Abstract][Full Text] [Related]
12. [Augmentation therapy with human alpha 1-protease inhibitor: whom to treat when?].
Wencker M
Med Klin (Munich); 1999 Mar; 94(3):137-9. PubMed ID: 10218347
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough.
Balbi B; Ferrarotti I; Miravitlles M
Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962
[No Abstract] [Full Text] [Related]
14. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.
Lieberman J
Chest; 2000 Nov; 118(5):1480-5. PubMed ID: 11083705
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
16. Augmentation therapy in alpha-1 antitrypsin deficiency.
Heresi GA; Stoller JK
Expert Opin Biol Ther; 2008 Apr; 8(4):515-26. PubMed ID: 18352854
[TBL] [Abstract][Full Text] [Related]
17. Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency.
Tortorici MA; Rogers JA; Vit O; Bexon M; Sandhaus RA; Burdon J; Chorostowska-Wynimko J; Thompson P; Stocks J; McElvaney NG; Chapman KR; Edelman JM
Br J Clin Pharmacol; 2017 Nov; 83(11):2386-2397. PubMed ID: 28662542
[TBL] [Abstract][Full Text] [Related]
18. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group.
Schluchter MD; Stoller JK; Barker AF; Buist AS; Crystal RG; Donohue JF; Fallat RJ; Turino GM; Vreim CE; Wu MC
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):796-801. PubMed ID: 10712324
[TBL] [Abstract][Full Text] [Related]
20. The direct medical costs of alpha(1)-antitrypsin deficiency.
Mullins CD; Huang X; Merchant S; Stoller JK;
Chest; 2001 Mar; 119(3):745-52. PubMed ID: 11243952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
